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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy, in part
due to the overexpression of inhibitors of apoptosis proteins (IAPs). Smac is an endogenous IAP-antagonist, which
renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac
mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management.
Methods: Cell viability assays and protein expression analysis were performed using WST-1 reagent and Western
blotting, respectively. Apoptosis was detected by annexin V/propidium iodide staining. In vivo tumor growth and
survival studies were performed in murine PDAC xenografts.
Results: JP and gemcitabine (Gem) inhibited PDAC cell proliferation with additive effects in combination. The
percentage of early apoptotic cells in controls, JP, Gem and JP + Gem was 17%, 26%, 26% and 38%, respectively.
JP-induced apoptosis was accompanied by PARP-1 cleavage. Similar additive anti-proliferative effects were seen for
combinations of JP with doxorubicin (Dox) and docetaxel (DT). The JP + Gem combination caused a 30% decrease
in tumor size in vivo compared to controls. Median animal survival was improved significantly in mice treated with
JP + Gem (38 d) compared to controls (22 d), JP (28 d) or Gem (32 d) (p = 0.01). Animal survival was also
improved with JP + DT treatment (32 d) compared to controls (16 d), JP (21 d) or DT alone (27 d).
Conclusions: These results warrant further exploration of strategies that promote chemotherapy-induced apoptosis
of tumors and highlight the potential of Smac mimetics in clinical PDAC therapy.
Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related deaths in the United
States. Prognosis of PDAC patients is very poor mostly
due to the late diagnosis, aggressive nature of disease
and an unusually high resistance to chemotherapy and
radiation [1-3]. Despite advancements in diagnostic and
surgical procedures and treatments, the overall 5-year
survival remains less than 5% [1]. Surgical resection
remains the only option for long-term survival of
patients. However, locally extended and metastatic dis-
ease limits the use of this procedure to only about 10%
of patients [4]. Therefore, t h em a j o r i t yo fp a n c r e a t i c
cancer patients are treated with systemic therapies.
Gemcitabine (Gem), a fluorinated pyrimidine antagonist,
is currently the most active single agent for locally
advanced, non-operable and metastatic PDAC. However,
Gem is only effective in a subset of patients, and
improvements in overall survival remain considerably
modest [5]. Several other cytotoxic and chemotherapy
agents such as cisplatin, fluorouracil, erlotinib, oxalipla-
tin, docetaxel and irinotecan have been tested as sec-
ond-line chemotherapy or in combination with Gem for
PDAC. However, most of these studies have failed to
show any significant improvement in overall patient sur-
vival compared to single agent Gem [6-12]. Therefore,
there is an urgent need for the development of thera-
peutic strategies that target novel mechanisms, and are
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Many cancer cells possess apoptotic dysfunction that
correlates with tumor aggressiveness and resistance to
conventional chemotherapy [13]. Various antiapoptotic
proteins including inhibitors of apoptosis (IAPs) have
been linked to cancer cell escape from apoptosis [14,15].
A high percentage of pancreatic cancer cell lines and
tumors express IAPs, including X-linked IAP (XIAP)
[16-18] at elevated levels compared to normal tissue.
Manipulating IAPs has been identified as a promising
approach for cancer treatment. Second-mitochondria
derived activator of caspase (Smac) is a mitochondrial
protein released into the cytosol upon apoptosis induc-
tion or mitochondrial dysfunction. Smac inhibits IAPs
and promotes caspase activation and apoptosis [19,20].
Recently, small-molecule mimetics of Smac have been
developed that can promote cancer cell apoptosis either
alone or in combination with other proapoptotic agents
[16,21,22]. In fact the Smac mimetic JP1201 (JP) has
recently been shown to augment the Gem response in
PDAC MIA PaCa-2 cells [23].
In the present study we evaluated the effect of JP on
the in vitro and in vivo therapeutic efficacy of various
cytotoxic chemotherapy agents in an effort to provide a
more effective antitumor strategy for PDAC.
Methods
Cell culture and reagents
H u m a nP D A Cc e l ll i n e s ,A s P C - 1 ,P a n c - 1 ,B x P C - 3a n d
MIA PaCa-2 were obtained from the American Type
Culture Collection (ATCC, Rockville, MD). Cell lines
were cultured in RPMI 1640 medium (Sigma Chemical
Co., St. Louis, MO) supplemented with 10% fetal bovine
serum (FBS) and 100 U/ml penicillin/streptomycin solu-
tion (Sigma) at 37°C in a humidified 5% CO2 atmo-
sphere. JP was obtained from Joyant Pharmaceuticals
(Dallas, TX), Gem was purchased from Eli Lilly Cor-
porations (Indianapolis, IN), doxorubicin (Dox) was pur-
chased from Ben Venue Laboratories (Bedford, OH) and
docetaxel (DT) was purchased from Sanofi-aventis
(Bridgewater, NJ).
Cell viability assay
In vitro cell viability of PDAC cell lines was evaluated by
using the colorimetric WST-1 reagent (Roche Diagnos-
tics, Indianapolis, IN) as described earlier [24]. The
assay is based on the ability of viable cells to cleave the
sulfonated tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-
2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfo-
nate) by mitochondrial dehydrogenases. Briefly, PDAC
cells (4,000 cells per well) were plated in a 96-well plate
in regular growth medium and after 16 hours the med-
ium was replaced with 2% FBS containing medium.
After 5 hours incubation the cells were treated with JP,
Gem, Dox or DT, either alone or in combination. After
additional incubation of 72 hours, 10 μl WST-1 reagent
was added in each well followed by incubation for 2
hours. The absorbance at 450 nm was measured using a
microplate reader.
Western blot analysis
A monolayer of cells at 75 to 80% confluence was
placed in 2% FBS containing medium for at least 5 hour
before treatment with JP (10 μM), gemcitabine (10 μM)
for 24 hours. Cells were lysed and equal amounts of
total protein were separated by SDS-PAGE and trans-
ferred to PVDF membranes (Bio-Rad, Hercules, CA).
The membranes were blocked for 1 hour at room tem-
perature with gentle shaking in TBS-T (10 mM Tris-
HCl (pH 7.6), 150 mM NaCl, 0.05% Tween 20). The
membranes were incubated overnight at 4°C with the
following antibodies: phospho-JNK, (Santa Cruz Bio-
technologies, Santa Cruz, CA), poly (ADP-ribose) poly-
merase-1 (PARP-1) (Cell Signaling Technology, Beverly,
MA), a-tubulin or GAPDH (Sigma). The membranes
were then incubated with corresponding HRP-conju-
gated secondary antibodies (Pierce Biotechnologies,
Rockford, IL) for 1 hour at room temperature. Specific
bands were detected using the enhanced chemilumines-
cence reagent (ECL, Perkin Elmer Life Sciences, Boston,
MA) on autoradiographic film and quantitated by
densitometry.
Apoptosis assay by Annexin V-FITC and propidium iodide
(PI) staining
Effect of JP and Gem on AsPC-1 cell apoptosis was
detected by using the Annexin V-FITC apoptosis detec-
tion kit (BioVision, CA) as per manufacturer’sp r o t o c o l .
Briefly, AsPC-1 cells were grown in 10% serum contain-
ing medium up to 80% confluence, medium was chan-
ged to 2% serum containing medium and incubated for
5 hours and then treated with JP (10 μM) and Gem (10
μM) for 12 hours. After incubation, cells were trypsi-
nized and suspended in 1 ml of low serum medium.
From each cell suspension 2 × 10
5 cell were centrifuged
and re-suspended in 500 μl 1X binding buffer. In each
sample 5 μl of Annexin V-FITC and 5 μlo fP Iw a s
added, incubated for 5 minutes in dark and immediately
analyzed by flow cytometry (FACS Calibur System, BD
Biosciences, Franklin Lakes, NJ). The annexin V - FITC
positive and PI-negative cells were considered to be
early apoptotic cells.
Animal Studies
All animal studies were performed in accordance with
the Institutional Animal Care and Use Committee at the
University of Texas Southwestern Medical Center
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using 4-6 weeks old SCID mice purchased from an on
campus facility. Tumor growth experiments were per-
formed by orthotopically injecting 1 × 10
6 Panc-1 cells.
Animals were examined by ultrasound and randomized
into treatment groups when tumor size averaged
500 mm
3 at approximately 8 weeks after tumor cell
injection. Animals were injected intraperitoneally with
PBS (control), JP (6 mg/kg in 100 μl PBS, three times
weekly) and Gem (25 mg/kg in 100 μl PBS, three times
weekly), either alone or in combination. Three mice
from each treatment group were sacrificed at 24 hours
of therapy while the remaining animals in each group
received 2 weeks of therapy prior to sacrifice.
Animal survival studies were conducted in an intra-
peritoneal PDAC tumor model as previously described
[25]. Female SCID mice received 0.75 × 10
6 human
AsPC-1 cells intraperitoneally. The animals were ran-
domly grouped (n = 6 to 8 per group) and treated intra-
peritoneally with PBS (control), JP (6 mg/kg in 100 μl
PBS, twice weekly), Gem (100 mg/kg in 100 μlP B S ,
twice weekly) and DT (3 mg/kg in 100 μlP B S ,t w i c e
weekly), either alone or in combination for 14 days or
as maintenance therapy. Animal weight was measured
twice weekly and all animals were examined daily for
signs of distress or development of jaundice. Moribund
mice at risk for distress were euthanized in accordance
with the local animal care committee protocol. Subse-
quently, animals were examined for presence and extent
of intra-abdominal tumor.
Statistical analysis
In vitro cell proliferation assay results are expressed as
mean ± standard deviation. Statistical significance was
analyzed by the two-tailed Student’s t-test using Graph-
Pad Prism 4 Software (GraphPad Software, San Diego,
CA). For in vivo studies, statistical analysis was per-
formed by ANOVA for multiple group comparison and
Student’s t-test for the individual group comparison. In
survival studies, statistical differences were analyzed by
nonparametric survival statistics and logrank test. Values
of p < 0.05 were considered to represent statistically sig-
nificant group difference.
Results
Effect of JP and Gem on PDAC cell proliferation
In vitro WST-1 assay was performed to examine the
effect of JP and Gem on PDAC cell proliferation. In
AsPC-1 cells, JP and Gem significantly inhibited the cell
proliferation. After 72 hours of incubation, JP (1 μM)
and Gem (500 nM) inhibited the AsPC-1 cell prolifera-
tion by 31% and 58%, respectively (Figure 1). The
combination of JP and Gem had an additive effect
on inhibition of AsPC-1 cell proliferation, with an
inhibition in cell proliferation of 70% after 72 hours of
incubation (Figure 1). At these concentrations, the inhi-
bition in cell proliferation of other PDAC lines in JP,
Gem and JP + Gem groups were 54%, 10% and 79% for
Panc-1; 42%, 56% and 77% for BxPC-3; and 9%, 43%
and 77% for MIA PaCa-2, respectively.
Effect of JP and Gem on PDAC apoptosis
We examined if the inhibition in AsPC-1 cell viability by
JP and Gem could in part be due to induction of apop-
tosis. Annexin V/PI staining assay revealed an increase
in early apoptotic cells by JP and Gem treatment that
was further increased by combination of these agents
(Figure 2A). At 10 μM concentration of either agent,
the percentage of early apoptotic cells was 17% in con-
t r o l s ,2 6 %i nJ Po rG e m ,a n d3 8 %i nt h eJ P+G e m
group. (Figure 2A).
We also measured cleavage of PARP-1 protein, a cas-
pase-dependent apoptosis-marker protein, after JP and
Gem treatment. A significant increase in the expression
of cleaved PARP-1 protein was observed after treatment
with JP, but not after exposure to Gem (Figure 2B).
Combination effects of JP and doxorubicin or docetaxel
on PDAC cell proliferation
We next evaluated if JP can sensitize other chemothera-
peutic agents. In vitro WST-1 assay revealed that JP,
Dox and DT inhibited the proliferation of all four
PDAC cell lines tested in a dose-dependent manner
(Figure 3). Interestingly, the combinations of JP with
either doxorubicin or docetaxel had additive effects on
inhibition of proliferation of PDAC cell lines (Figure 3).
At intermediate concentrations of these agents, inhibi-
tion in cell proliferation in AsPC-1 cells in JP (5 μM),
Dox (1 μM), DT (1 μM), JP + Dox and JP + DT groups
were 40%, 39%, 48%, 73% and 73%, respectively. Similar
additive combination effects of JP with Dox or DT were
observed regarding Panc-1, MIA PaCa-2 and BxPC-3
proliferation (Figure 3).
Evaluation of PARP-1 cleavage after JP, Dox and DT
treatment by Western blot analysis revealed that Dox
and DT had no effect on PARP-1 cleavage, while JP
exposure led to a significant increase in PARP-1 clea-
vage (Figure 4).
In vivo effects of JP addition to gemcitabine and
docetaxel
The antitumor impact of JP, Gem and DT, either alone
or in combination, was evaluated in murine PDAC
xenografts. In an orthotopic Panc-1 xenograft model,
tumor weights were measured at completion of therapy
and compared to tumors harvested at 24 hours of ther-
apy (Figure 5). The increase in tumor weight was 87%
in controls, while Gem and JP treatment alone trended
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JP + Gem combination treatment resulted in decreased
tumor weight compared to that at treatment start, with
a mean reduction of approximately 30% (p < 0.05 verses
control) (Figure 5). In survival studies with maintenance
therapy, a statistically significant improvement in animal
survival was observed in mice treated with the combina-
tion of JP + Gem (median: 38 days, p = 0.01) compared
to controls (22 days) or single agent treatment with JP
(28 days) or Gem (32 days, p = 0.02) (Figure 6A). Ani-
mal survival was also significantly improved in a 14-day
combination treatment with JP + DT (32 days) as com-
pared to controls (16 days) or single agent treatment
with JP (21 days) or DT (27 days) (Figure 6B). In addi-
tion to survival impact, we also evaluated the treatment
effects of JP and DT on inhibition of local tumor growth
in subcutaneous AsPC-1 pancreatic cancer xenografts.
JP enhanced the DT-mediated local antitumor effects:
compared with controls, addition of JP enhanced the
inhibition in net tumor growth by DT of 57% to 91% in
combination (p = NS), respectively (data not shown).
Discussion
Resistance to conventional chemotherapy continues to
be a challenge in PDAC. Acquired resistance to apopto-
sis, which is prevalent in PDAC, is a critical pathway
that promotes resistance to conventional chemotherapy
[17,18]. Therefore, targeting apoptosis resistance has
emerged as an attractive novel cancer therapeutic strat-
egy [26,27]. Small molecules with proapoptotic activity
are particularly advantageous, as they are membrane
permeable, inhibit antiapoptotic molecules, augment
efficacy of current therapeutics and minimize side
effects of single agent therapy. Smac mimetics represent
a novel class of anticancer drugs that are currently
undergoing clinical evaluation [28]. We studied the
Figure 1 Effects of JP and Gem on AsPC-1 cell proliferation in vitro. AsPC-1 cells were plated on a 96-well plate and were treated with PBS
(Control, C), JP or Gem, either alone or in combination. After 72 hours incubation, 10 μl WST-1 reagent was added in each well and incubated
for additional 2 hours. The resulting number of viable cells was calculated by measuring absorbance of color produced in each well. Data are
representative of mean values ± SD of triplicate determinants. Symbol * represents P values of less than 0.0004.
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JP1201, in combination with the deoxycytidine analogue
gemcitabine and the cell-mitosis inhibitor docetaxel in
experimental pancreatic cancer.
Human PDAC cells lines have been shown to display
marked heterogeneity towards Gem [29]. A similar hetero-
geneity regarding Gem sensitivity was seen in our four
lines tested. Nevertheless, we observed that JP inhibited
the proliferation of all four PDAC cell lines, and that the
combination of JP + Gem had additive effects. Antitumor
activity of Smac mimetics is mediated through induction
of apoptosis. We therefore explored if proliferation inhibi-
tion of PDAC cells after combination therapy is in part
due to induction in apoptosis. Detection of early apoptotic
cells by annexin V/PI staining demonstrated that JP and
Gem moderately induced apoptosis, and JP + Gem had an
additive effect. Smac mimetic-induced apoptosis involves
caspase activation that cleaves PARP-1, a DNA repair
enzyme, to produce 89 kDa or 24 kDa cleavage product.
W eo b s e r v e dad r a m a t i ci n c r e a s ei nt h e8 9k D aC -
terminus cleavage product of PARP-1 after JP treatment
indicating the involvement of caspases in JP-induced
apoptosis. While Gem treatment for 12 hours caused an
increase in annexin V positive cells, no PARP-1 cleavage
was detected after 24 hours of Gem treatment; this finding
is likely related to the fact that 24 hours incubation may
not be enough to cause detectable levels of PARP-1 clea-
vage. Based on in vitro additive anti-proliferative and proa-
poptotic effects of JP and Gem together, we examined
effects of these agents on in vivo animal survival and
observed that the JP + Gem combination significantly
increases the animal survival compared with controls or
monotherapy. Our findings corroborate a recently pub-
lished report [23] that the Smac mimetic JP1201 enhances
chemotherapy response of Gem in PDAC cell lines;
accordingly, the JP-mediated increase in antiproliferative
response after Gem was greatest in Panc-1 cells followed
by MIA PaCa-2, BxPC-3 and AsPC-1 cells. Correspond-
ingly, a 30% reduction in tumor weight was observed in
our orthotopic Panc-1 tumor experiment compared to a
Figure 2 Effects of JP and Gem on PDAC cell apoptosis.A s P C - 1c e l l sw e r et r e a t e dw i t hJ P( 1 0μM) and Gem (10 μM) either alone or in
combination. (A) The early apoptotic cells (lower right quadrant) were measured by flow cytometry after staining with FITC-conjugated annexin
V and propidium iodide. The percentage of cells in each quadrant is indicated within the quadrant. (B) PARP-1 cleavage was measured by
Western blotting. The total cell lysate was subjected to SDS-PAGE and immunoblotted with PARP-1 antibody, which recognizes full-length (116
kDa) and cleaved (89 kDa) PARP-1 protein. Expression of a-tubulin (55 kDa) was analyzed as loading control on a separate gel. Data are
representative of two independent experiments with similar results.
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lines. Cells were plated on 96-well plates and treated with JP, Dox or DT, either alone or in combination. X-axis numbers represent treatment
concentrations of JP, Dox and DT. Number 1 represents control, number 2 represents JP 100 nM, Dox or DT 10 nM, number 3 represents JP 1
μM, Dox or DT 100 nM, number 4 represents JP 5 μM, Dox or DT 1 μM, and number 5 represents JP 10 μM, Dox or DT 10 μM.
Figure 4 Effects of JP, Dox and DT on PAPR-1 cleavage. AsPC-1 cells were treated with JP (10 μM), Dox (10 μM) or DT (10 μM), either alone
or in combination. PARP-1 cleavage was measured by Western blotting. The total cell lysate was subjected to SDS-PAGE and immunoblotted
with PARP-1 antibody, which recognizes full-length (116 kDa) and cleaved (89 kDa) PARP-1 protein. Expression of GAPDH (37 kDa) was analyzed
as loading control on a separate gel. Data are representative of two independent experiments with similar results.
Awasthi et al. BMC Cancer 2011, 11:15
http://www.biomedcentral.com/1471-2407/11/15
Page 6 of 950% reduction in orthotopic MIA PaCa-2 tumors in the
previous study [23]. In addition, a significant improvement
in animal survival was observed with JP + Gem treatment
in AsPC-1 xenografts compared with JP or Gem alone
similar to the previous study [23]. Of note, the lack of a
significant reduction in tumor growth (Figure 5) by Gem
alone in the present study is likely merely a result of the
small number of animals in that tumor growth experi-
ment, and does not pose a conflict with the significant
improvement in animal survival seen after the same treat-
ment (Figure 6A). Altogether, our results can thus support
a more generalizable phenomenon in this context, as JP
combination benefits have been obtained in four PDAC
cell lines, and with other cytotoxic agents beyond
gemcitabine.
Smac mimetics have been shown to enhance antitu-
mor effects of several agents including cisplatin [30] and
TRAIL [23,31] in different cancer types. Docetaxel is a
clinically well established anti-mitotic chemotherapy
treatment for several cancers including breast, ovarian
and non-small cell lung cancer [32]. We explored the
combination treatment effects of JP with other che-
motherapy agents such as doxorubicin and docetaxel in
experimental pancreatic cancer. In vitro studies showed
that JP significantly enhanced antiproliferative effects of
Dox and DT in all four PDAC cell lines tested. In addi-
tion JP and DT combination had significant enhanced
effect on tumor regression and animal survival in pan-
creatic cancer xenografts. These results indicate that a
potential clinical benefit to Smac-mimetic combination
therapies does not appear to be chemotherapeutic agent
specific, and that such approach may carry a wide range
of indications.
Small molecule Smac mimetics have been shown to be
particularly advantageous in overcoming chemotherapy
resistance when resistance occurs through modulation
of the NFkB-IAP pathway. Since several pancreatic can-
cer cell lines and tumors have been shown to overex-
p r e s sI A P s( 1 6 - 1 8 ) ,t r e a t m e n to fP D A Cw i t hJ Pi n
combination with other chemotherapeutic agents shows
specific promise for becoming effective for this disease.
Our present study supports this notion through preli-
minary, preclinical evidence. The potential to render tra-
ditionally non-effective agents more effective for clinical
PDAC therapy is particularly intriguing in this context.
Conclusions
Chemotherapy-induced apoptosis of PDAC can be
enhanced through JP1201, a Smac mimetic. The resulting
combination improves apoptotic response, antiproliferative
Figure 5 Effects of JP and Gem on animal tumor burden. Panc-
1 cells (1 × 10
6) were injected orthotopically in SCID mice. Eight
weeks after tumor cell injection mice were randomized and treated
with PBS (control), JP, Gem and JP + Gem. Three mice in each
group were sacrificed at 24 hours of therapy, with a mean tumor
weight of 0.594 ± 0.08 g. The remaining mice were sacrificed after 2
weeks. Symbol * represents p < 0.05 verses control (CNTL). Figure 6 Effects of JP, Gem and DT, either alone or in
combination on animal survival. AsPC-1 cells (0.75 × 10
6) were
injected intraperitoneally in SCID mice and treatment started after
12 days. (A) Mice were treated with PBS (control), JP, Gem and
JP + Gem for 14 days. The curve represents the survival time from
the beginning of therapy. The p values for survival differences after
Gem and JP + Gem versus control are 0.02 and 0.01, respectively; JP
+ Gem versus Gem: p = 0.06; JP + Gem versus JP: p = 0.02. (B) Mice
were treated with PBS (control), JP, DT and JP + DT for 14 days. The
curve represents the survival time from the beginning of therapy.
The p values for survival differences after DT or JP + DT treatment
versus control were 0.006; JP + Gem versus Gem: p = 0.05; JP +
Gem versus JP: p = 0.04.
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strategy shows promise for future clinical evaluation.
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